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Background/aim: Diaphragm thickness and mobility assessed by ultrasound in individuals with Chronic Obstructive Pulmonary
Disease (COPD) reflect the function of the diaphragm. The aim of this study is to compare the diaphragm thickness, mobility, and
thickening fraction in individuals with COPD of different severity and healthy individuals and examine the relationship between these
parameters and pulmonary function test parameters.
Materials and methods: A cross-sectional observational study design was used. Thirty individuals (mild = 11; moderate = 13; severe
= 6) with COPD and 29 healthy male individuals aged between 40–75 years were included in the study. The individuals included in
the study were evaluated between October 2020/May 2021. Pulmonary functions were measured with a spirometer, while diaphragm
thickness, mobility, and thickening fraction were measured by ultrasound.
Results: The right and left diaphragm thickness, mobility, thickness variation, thickening fraction, and mobility were lower in individuals
with COPD than in healthy individuals (p < 0.05). The left Functional Residual Capacity (FRC) diaphragm thickness, right Total Lung
Capacity (TLC), and FRC diaphragm thickness were higher in mild COPD than moderate COPD and moderate COPD than severe
COPD (p < 0.05). The right diaphragmatic thickening fraction and rate were higher in mild COPD than in moderate and severe COPD
(p < 0.05). The left mobility was lower in severe COPD than in mild COPD (p < 0.05).
Conclusion: Diaphragm ultrasound parameters decrease as disease severity increases in individuals with COPD. We think that adding
diaphragm ultrasound parameters together with pulmonary function test to the evaluation of individuals with COPD will provide
additional contributions to determining the course of the disease.
Key words: Diaphragm thickness, diaphragm mobility, diaphragm thickening fraction, COPD, respiratory muscle function

1. Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a
common, treatable, and preventable disease characterized
by persistent respiratory signs and airway limitation
due to airway and/or alveolar abnormality resulting
from exposure to harmful gases or particles and causing
abnormal lung development [1]. COPD is the leading cause
of mortality and morbidity worldwide, causing significant
social and economic burdens [2–4]. The World Health
Organization (WHO) stated that COPD is the 3rd leading
cause of death, and COPD-related deaths will be more
than 4.5 million in 2030 [5,6]. While respiratory diseases
constitute approximately 6% of total health expenditures
in European Union countries, COPD constitutes 56% of
these expenditures [7]. In individuals with COPD, chronic

inflammation causes structural changes, narrowing of the
small airways, and destruction of the lung parenchyma,
resulting in loss of alveoli and decreased lung elastic recoil
strength. Loss of small airways also causes airway limitation
and mucociliary dysfunction that are characteristic of the
disease [1,8].
In addition to pulmonary changes, extrapulmonary
changes occur in individuals with COPD. Skeletal muscle
dysfunction is among the most common extrapulmonary
changes. Skeletal muscle dysfunction affects both
respiratory and extremity muscles [9]. Respiratory muscle
function is primarily characterized by respiratory muscle
strength and endurance. Loss of strength and/or endurance
causes diaphragm weakness and impaired performance
[10]. In individuals with COPD, the diaphragm shortens
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due to pulmonary hyperinflation, the diaphragm is
positioned in a nonoptimal position and works with a
mechanical disadvantage, leading to respiratory muscle
dysfunction [11–13]. It is stated that skeletal muscle
thickness measurement is used in the evaluation of muscle
loss in COPD, and diaphragm mobility is useful in the
treatment and management of COPD. In the literature,
there are studies examining diaphragm thickness, mobility,
and thickening fraction in COPD and healthy individuals
[14,15]. However, the number of studies examining the
change of diaphragm thickness, mobility, and thickening
fraction with disease severity in individuals with COPD is
insufficient in the literature. Moreover, while diaphragm
ultrasound parameters were evaluated separately in other
studies in the literature; in this study, all of the diaphragm
ultrasound parameters were evaluated. In addition,
while these parameters were examined unilaterally in
the literature; in this study, the right and left sides were
examined separately. The aim of this study is to compare
diaphragm thickness, mobility, and thickening fraction in
individuals with COPD of different severity and healthy
individuals and examine the relationship between these
parameters and pulmonary function test parameters.
2. Materials and methods
A cross-sectional observational study design was used.
The number of individuals to be included in the study
was determined using the G*Power 3.1 software. It
was observed that the effect size of the right diaphragm
thickening fraction % results obtained in the reference
study was at a strong level (d = 1.047). As a result of the
sample size analysis carried out considering that a lower
level of effect size (d = 0.9) could be obtained, it was
calculated that 80% power could be obtained at a 95%
confidence interval when at least 42 individuals (at least
21 for each group) were included in the study [14]. In the
study, 59 male individuals (30 individuals with COPD and
29 healthy individuals) followed up by Bolu Abant İzzet
Baysal University, Faculty of Medicine, Department of
Chest Diseases were evaluated. The individuals included in
the study were evaluated between October 2020/May 2021.
According to the effect size of the difference between the
groups (d = 1.325) in the % results of the right diaphragm
thickening fraction obtained in these individuals, it was
calculated that our study reached a power of 98.1% at a
95% confidence level.
Volunteers who were aged between 40–75 years and
diagnosed with COPD and who did not change their
medication for at least three weeks were included in the
study. Individuals who had orthopedic, neurological, lung
diseases other than COPD, unstable angina, a history
of previous myocardial infarction, severe heart failure
resistant to medical treatment, uncontrolled hypertension

and cancer, who had undergone major surgery in the last
six months and were in the exacerbation period of COPD
were excluded from the study. Individuals without any
diagnosed disease were included in the healthy group. The
study was initiated after obtaining the necessary permission
from Bolu Abant İzzet Baysal University (BAİBU) Clinical
Research Ethics Committee (date: 19.10.2020 number:
420). Individuals were informed about the study, and a
written consent form was acquired.
The individuals’ demographic information (namesurname, sex, age), height in meters (m), and body weight
in kilograms (kg) were recorded. Furthermore, the body
mass index (BMI) was recorded as kg/m², using the ratio
of body weight to height squared formula.
2.1. Pulmonary function test
Pulmonary functions were evaluated using a spirometer
(Cosmed Microquark-PC Based Spirometer, Rome, Italy)
[16]. Forced expiratory volume in the first second (FEV1),
forced vital capacity (FVC), FEV1/FVC, peak expiratory
flow (PEF), flow rate between 25% and 75% of vital
capacity during forced expiration (FEF%25-75) and maximal
expiratory flow (MEF 25%, 50%, 75%) were evaluated
by the pulmonary function test [17]. Evaluations were
repeated at least three times. The best of correct maneuvers
was expressed as a percentage of expected values [18].
Individuals with COPD were classified according to
the severity of airway limitation as mild (FEV1 ≥ 80%),
moderate (50% ≤ FEV1 < 80%), severe (30% ≤ FEV1 <
50%), and very severe (FEV1 < 30%) [1].
2.2. Diaphragm thickness and mobility
Diaphragm thickness and mobility were evaluated with
the HI VISION Preirus ultrasound device (Hitachi
Medical Systems, Tokyo, Japan). A 6-13 MHz linear probe
was utilized for diaphragm thickness, whereas a 1-5 MHz
convex probe was used for diaphragm mobility (Figure 1).
Diaphragm thickness in individuals was measured twice,
at the end of expiration for Functional Residual Capacity
(FRC) and at the end of maximal inspiration for Total
Lung Capacity (TLC). Diaphragm mobility was calculated
as the displacement length of the apex of the diaphragm
between the FRC and TLC lung volumes. Diaphragm
thickness was measured from the 8th or 9th intercostal
space, while diaphragm mobility was measured from the
costal line junction of the medial axillary line (Figures 2,3).
Diaphragm thickness and mobility measurements were
repeated on the right and left sides [15,19]. The difference
between the TLC and FRC diaphragm thicknesses was
expressed as the diaphragm thickening, the ratio of the
diaphragm thickening amount to the FRC diaphragm
thickness was expressed as the diaphragm thickening
fraction, and the ratio of the TLC diaphragm thickness
to the FRC diaphragm thickness was expressed as the
thickening ratio.
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Figure 1. Diaphragm thickness and mobility
measurement.

Figure 2. Diaphragm thickness measurement; A) TLC B) FRC.

Figure 3. Diaphragm mobility measurement.
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2.3. COPD assessment test
The COPD assessment test (CAT) was used in the
evaluation of health status impairment in individuals with
COPD. CAT is an 8-item test consisting of questions that
evaluate the severity of symptoms such as shortness of
breath, cough and sputum, and the impact of the disease
on daily life. Each question is scored between 0–5 and
the total score ranges from 0 to 40 points. A score of 0
represents the best and a score of 40 represents the worst
state of health [20].
2.4. Charlson comorbidity index
Charlson comorbidity index was used to evaluate
comorbidities. Charlson et al. in this index, comorbidities
were scored between 1 and 6 according to disease severity.
Individuals’ Charlson score was found by summing the
scores determined for comorbidities [21].
2.5. MMRC dyspnea scale
The perception of shortness of breath during activities
of daily living was evaluated using the MMRC Dyspnea
Scale. Individuals with COPD were asked to choose the
statement that best described the severity of dyspnea
among 5 statements scored between 0 and 4 [22].
2.6. Statistical analysis
Data were analyzed using SPSS 25.0 (IBM SPSS Statistics
25 software (Armonk, NY: IBM Corp.)) packaged
software. Continuous variables were expressed as mean

± standard deviation, median (minimum-maximum
values), and categorical variables were expressed as
numbers and percentages. The conformity of the data to
the normal distribution was examined using the ShapiroWilk test. In the analysis of independent group differences,
the independent samples t-test and One Way Analysis of
Variance (post hoc: Tukey Test) were used when parametric
test assumptions were provided, and the Mann-Whitney U
test and Kruskal Wallis Variance Analysis (post hoc: Mann
Whitney U test with Bonferroni correction) were used
when assumptions were not provided. Chi-square analysis
was performed to analyze differences between categorical
variables. Moreover, Spearman’s correlation analysis
was conducted to examine the relationships between
continuous variables. The value of p < 0.05 was considered
statistically significant in all analyses.
3. Results
The flow chart of the participants is shown in Figure 4.
Upon comparing the age, height, body weight, and BMI
values of individuals, there was no significant difference
between individuals with COPD and healthy individuals
(p > 0.05). There was a significant difference between
individuals with COPD and healthy individuals in terms
of smoking history, FEV1, FVC, FEV1/FVC, PEF, and
FEF25–75% (p < 0.05) (Table 1).

Figure 4. Participants flow chart.
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When the diaphragm ultrasound parameters of
individuals with COPD and healthy individuals were
compared, all parameters were statistically decreased in
individuals with COPD compared to healthy individuals
(p < 0.05) (Table 2).
The comparison of diaphragm ultrasound parameters
in individuals with COPD of different severity and healthy
individuals is shown in Table 3.
FEV1%, FVC%, PEF%, MEF 25%, MEF 50%, and MEF
75% were positively correlated with the left and right
TLC diaphragm thickness, FRC diaphragm thickness,
mobility, and right diaphragm thickness variation (p
< 0.05). FEV1%, FVC%, PEF%, MEF 25%, MEF 50%,
and MEF 75% were positively correlated with the left

diaphragm thickness variation (p < 0.05). FEV1%, FVC%,
and MEF 50% were positively correlated with the right
diaphragm thickening fraction % and thickening ratio (p
< 0.05). The left diaphragm thickening fraction % and left
diaphragm thickening ratio values were not correlated
with any pulmonary function test parameters (p > 0.05).
Diaphragm ultrasound parameters were not correlated
with BMI, CAT, and CCI score (p > 0.05). Left and right
TLC diaphragm thickness, FRC diaphragm thickness
mobility were negatively correlated with MMRC dyspnea
score (p < 0.05); left and right diaphragm thickening,
diaphragm thickening fraction and ratio were not
correlated with MMRC dyspnea score (p > 0.05) (Table
4).

Table 1. Demographic and clinical characteristics of individuals with COPD and healthy individuals, mean ± S.D.,
median (min-max) or n (%).

Age (years)
Height (cm)
Weight (kg)
BMI (kg/m²)
Smoking (pack*year)
FEV1
FVC
FEV1/FVC
PEF
FEF25–75%
CAT
CCI
Paroxysmal nocturnal dyspnea
Orthopnea
Resting shortness of breath
Activity shortness of breath

MMRC

Yes
No
Yes
No
Yes
No
Yes
No
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4

COPD (n = 30)

Healthy (n = 29)

p

63 (40–73)
167.13 ± 6.53
75.61 ± 16.17
27.05 (17.3–39.5)
46.5 (0–85)
70.13 ± 20.09
89 (36–115)
72.05 (40.7–80)
63.5 ± 20.78
42.77 ± 21.63
12.47 ± 7.19
2 (1–9)
12 (40)
18 (60)
13 (43.33)
17 (56.67)
22 (73.33)
8 (26.67)
30 (100)
0 (0)
1 (3.33)
6 (20)
5 (16.67)
12 (40)
6 (20)

54 (47–72)
169.34 ± 6.64
81.83 ± 10.46
27.8 (23.5–39.1)
6 (0–18)
96.28 ± 16.29
100 (76–143)
79.3 (70.3–88.7)
78.52 ± 20.24
80.14 ± 25.11
11 (4–29)
0 (0–2)
0 (0)
29 (100)
0 (0)
29 (100)
0 (0)
29 (100)
26 (89.66)
3 (10.34)
22 (75.86)
7 (24.14)
0 (0)
0 (0)
0 (0)

0.068
0.202
0.086
0.228
0.0001*
0.0001*
0.007*
0.0001*
0.007*
0.0001*
0.0001*
0.001*
0.001*
0.001*
0.112 γ

0.0001*

*: significant p value less than 0.05; t: independent samples t-test; z: Mann-Whitney U test; χ²: Chi-square test; γ:
Fisher exact chi-square test; BMI; Body mass index; FEV1: Forced expiratory volume in the first s; FVC: Forced
vital capacity; PEF: Peak expiratory flow; FEF%25-75: Flow rate between 25% and 75% of vital capacity during forced
expiration; CAT: COPD assessment test; CCI: Charlson comorbidity index; MMRC: Modified Medical Research
Council dyspnea scale.
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Table 2. Comparison of the diaphragm ultrasound parameters values in individuals with COPD and healthy individuals, mean ± S.D.,
median (min–max).

Left TLC diaphragm thickness (mm)
Left FRC diaphragm thickness (mm)
Left diaphragm thickening (mm)
Left diaphragm thickening fraction %
Left diaphragm thickening ratio
Left mobility (mm)
Right TLC diaphragm thickness (mm)
Right FRC diaphragm thickness (mm)
Right diaphragm thickening (mm)
Right diaphragm thickening fraction %
Right diaphragm thickening ratio
Right mobility (mm)

COPD
(n = 30)

Healthy
(n = 29)

p

4.13 ± 1.24
2.88 ± 0.76
1 (0.5–2.2)
44.15 ± 11.78
1.46 (1.13–1.68)
44.4 (28.1–51)
4.27 ± 1.27
3 ± 0.79
1 (0.5–2.3)
41.74 ± 10.06
1.41 ± 0.1
44.9 (27.6–52)

7 ± 0.33
3.73 ± 0.22
3.3 (2.8–3.6)
87.53 ± 4.68
1.86 (1.81–1.97)
58.2 (48.7–66.8)
7.08 ± 0.26
3.78 ± 0.21
3.3 (3.1–3.5)
87.53 ± 4.78
1.87 ± 0.05
59.8 (48.8–65.9)

0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*
0.0001*

*: significant p value less than 0.05; SD: Standard deviation; Min: Minimum; Max: Maximum; t: independent samples t-test; z: MannWhitney U test; TLC: Total lung capacity; FRC: Functional residual capacity.
Table 3. Comparison of diaphragm ultrasound parameters values in individuals with COPD of different severity mean ± S.D., median (min–
max).

Mild (1)

Moderate (2)

Severe (3)

(n = 11)

(n = 13)

(n = 6)

p

0.0001*
(Kwh = 19,161) (1–2, 1–3, 2–3)
0.0001*
Left FRC diaphragm thickness (mm)
3.51 ± 0.43
2.8 ± 0.64
1.92 ± 0.17
(F = 19,811) (1–2, 1–3, 2–3)
0.003*
Left diaphragm thickening (mm)
1.9 (0.9–2.2)
1 (0.5–1.9)
1 (0.7–1.1)
(Kwh = 11,715) (1–2,1–3)
0.003*
Left diaphragm thickening fraction %
52.5 (32.14–62.85) 39.13 (13.88– 47.61) 50 (36.84– 68.75)
(Kwh = 11,862) (1–2)
0.003*
Left diaphragm thickening ratio
1.52 (1.32–1.62)
1.39 (1.13–1.47)
1.5 (1.36–1.68)
(Kwh = 11,729) (1–2)
0.0001*
Left mobility (mm)
48.5 (46.6–51)
43.6 (34–47.6)
33.2 (28.1–34)
(Kwh = 23,687) (1–2,1–3)
0.0001*
Right TLC diaphragm thickness (mm) 5.45 ± 0.78
4 ± 0.91
2.72 ± 0.28
(F = 25,092) (1–2, 1–3, 2–3)
0.0001*
Right FRC diaphragm thickness (mm) 3.62 ± 0.44
2.96 ± 0.65
1.93 ± 0.15
(F = 21,008) (1–2, 1-3, 2-3)
0.0001*
Right diaphragm thickening (mm)
2 (1–2.3)
0.9 (0.7–1.9)
0.85 (0.5–0.9)
(Kwh = 18,113) (1–2,1–3)
0.0001*
Right diaphragm thickening fraction % 50.21 ± 8.91
35.2 ± 6.57
40.38 ± 7.34
(F = 11,583) (1–2, 1–3)
0.0001*
Right diaphragm thickening ratio
1.5 ± 0.09
1.35 ± 0.07
1.4 ± 0.07
(F = 11,556) (1–2, 1–3)
0.0001*
Right mobility (mm)
49 (47.8–52)
43.5 (35.1–49.7)
34.5 (27.6–35.6)
(Kwh = 22,430) (1–2,1–3)
Left TLC diaphragm thickness (mm)

5.4 (3.7–6.3)

3.4 (3–6.1)

2.95 (1.7–3.1)

*: significant p value less than 0.05; F: One-Way analysis of variance (post hoc: Tukey Test); Kwh: Kruskal Wallis H test (post hoc: Mann
Whitney U test with Bonferroni correction).
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0.203
0.283

0.204
0.280

0.979*
<0.001

0.907*
<0.001

0.898*
<0.001

0.792*
<0.001

0.447*
0.013

0.951*
<0.001

r
p

r
p

r
p

r
p

r
p

r
p

Left diaphragm thickening ratio

Left mobility (mm)

Right FRC diaphragm thickness r
(mm)
p

r
p

Left diaphragm thickening
fraction %

Right TLC diaphragm thickness r
(mm)
p

r
p

Left diaphragm thickening
(mm)

Right diaphragm thickening
(mm)

Right diaphragm thickening
fraction %

Right diaphragm thickening
ratio

Right mobility (mm)

0.781*
<0.001

0.361*
0.050

0.364*
0.048

0.714*
<0.001

0.732*
<0.001

0.746*
<0.001

0.818*
<0.001

0.101
0.597

0.100
0.598

0.522*
0.003

0.727*
<0.001

0.768*
<0.001

FVC%

0.269
0.150

–0.041
0.831

–0.035
0.856

0.081
0.669

0.245
0.192

0.221
0.241

0.264
0.159

–0.039
0.839

–0.038
0.843

0.045
0.814

0.279
0.135

0.222
0.239

FEV1/FVC

0.632*
<0.001

0.029
0.880

0.031
0.871

0.376*
0.041

0.544*
0.002

0.547*
0.002

0.571*
0.001

0.015
0.938

0.010
0.956

0.329
0.076

0.555*
0.001

0.535*
0.002

PEF%

0.760*
<0.001

0.288
0.122

0.295
0.113

0.555*
0.001

0.751*
<0.001

0.738*
<0.001

0.760*
<0.001

0.126
0.507

0.125
0.510

0.450*
0.013

0.745*
<0.001

0.728*
<0.001

FEF
%25–75

0.822*
<0.001

0.303
0.104

0.304 0.102

0.559*
0.001

0.835*
<0.001

0.787*
<0.001

0.833*
<0.001

0.137
0.472

0.135
0.477

0.463*
0.010

0.857*
<0.001

0.816*
<0.001

MEF
%25

0.837*
<0.001

0.445*
0.014

0.456
0.011

0.658*
<0.001

0.767*
<0.001

0.782*
<0.001

0.861*
<0.001

0.234
0.213

0.237
0.207

0.493*
0.006

0.771*
<0.001

0.774*
<0.001

MEF
%50

0.883*
<0.001

0.276
0.140

0.283
0.129

0.658*
<0.001

0.811*
<0.001

0.819*
<0.001

0.883*
<0.001

0.053
0.779

0.055
0.774

0.460*
0.011

0.818*
<0.001

0.808*
<0.001

MEF
%75

–0.057
0.763

–0.155
0.412

–0.154
0.417

–0.154
0.418

0.039
0.839

–0.017
0.931

–0.100
0.599

–0.205
0.276

–0.209
0.269

–0.185
0.327

0.060
0.753

–0.003
0.986

BMI

–0.485*
0.007

0.222
0.238

0.212
0.261

–0.215
0.254

–0.506*
0.004

–0.444*
0.014

–0.430*
0.018

0.273
0.144

0.271
0.148

–0.210
0.265

–0.484*
0.007

–0.468*
0.009

MMRC

–0.342
0.064

0.207
0.271

0.205
0.278

–0.090
0.637

–0.279
0.136

–0.256
0.171

–0.261
0.164

0.243
0.196

0.246
0.189

–0.062
0.746

–0.272
0.145

–0.270
0.149

CAT

0.142
0.455

–0.028
0.882

–0.029
0.877

0.029
0.877

0.068
0.720

0.097
0.609

0.048
0.801

0.178
0.347

0.181
0.339

0.142
0.454

0.058
0.763

0.077
0.687

CCI

*: significant p value less than 0.05; r: Spearman correlation coefficient; TLC: Total lung capacity; FRC: Functional residual capacity; FEV1: Forced expiratory volume in the first s;
FVC: Forced vital capacity; PEF: Peak expiratory flow; FEF%25-75: Flow rate between 25% and 75% of vital capacity during forced expiration; MEF: Maximal expiratory flow; BMI:
Body mass index; MMRC: Modified Medical Research Council dyspnea scale; CAT: COPD Assessment test; CCI: Charlson comorbidity index.

0.453*
0.012

0.611*
<0.001

0.893*
<0.001

r
p

Left FRC diaphragm thickness
(mm)

0.906*
<0.001

r
p

Left TLC diaphragm thickness
(mm)

FEV1%

Table 4. The relationship between diaphragm ultrasound parameters and pulmonary function test parameters, BMI, MMRC, CAT, CCI score in individuals with COPD.
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4. Discussion
In this study, it was observed that diaphragm thickness,
mobility, and thickening fraction decreased as COPD
severity increased, and these parameters were associated
with pulmonary function test parameters. Abd El Aziz
et al. found that diaphragm thickness decreased at TLC,
FRC, and RV in individuals with COPD, while Okura et
al. revealed that TLC diaphragm thickness decreased in
individuals with COPD compared to healthy individuals,
and there was no difference in FRC and RV thicknesses
between the three groups in their study conducted with
38 individuals with COPD, and 15 young and 15 elderly
healthy male individuals [23,24]. Jain et al. determined
that TLC and FRC diaphragm thickness decreased in
individuals with mild and moderate COPD, and FRC
diaphragm thickness increased in individuals with severe
COPD [25]. While the reason for the increase in diaphragm
thickness could not be fully explained, it was stated that
it might be due to the development of some adaptations
such as collagen deposition in severe obstruction. Ogan
et al. stated that the maximum (deep inspiration) and
minimum (tidal volume) diaphragm thicknesses were
normal in individuals with COPD due to the adaptation of
the diaphragm because of excessive work against increased
mechanical load [26]. Elsawy revealed that TLC and RV
diaphragm thicknesses were preserved in individuals with
COPD due to the sarcomere adaptation of the muscle
fiber protecting the static thickness of the diaphragm and
compensatory overuse hypertrophy with the increase
in COPD severity and hyperinflation [14]. In our study,
TLC and FRC diaphragm thicknesses were found to be
decreased in individuals with COPD compared to healthy
individuals. Based on the studies in the literature, we
think that this may be due to the etiological factors (such
as systemic inflammation, oxidative stress, and drugs)
that cause respiratory muscle dysfunction, especially
mechanical changes due to hyperinflation.
Paulin et al. showed that diaphragm mobility
decreased in individuals with COPD [27]. They stated that
the main reason for the decrease in diaphragm mobility
was air trapping and it was not affected by pulmonary
hyperinflation. Yamaguti et al. also demonstrated that
decreased diaphragm mobility in individuals with COPD
was associated with air trapping rather than pulmonary
hyperinflation and respiratory muscle strength [28].
In this study, they explained that abnormal diaphragm
mobility reflecting the respiratory muscle dysfunction
was mainly caused by the abnormal flow-volume
performance of the lung in individuals with COPD.
Similar to these studies, Shiraishi et al. also showed that
diaphragm mobility decreased in individuals with COPD
in comparison with the control group [29]. Corbellini et
al. on the other hand found that diaphragm mobility in

deep inspiration decreased in individuals with COPD due
to static pulmonary air trapping and dynamic pulmonary
hyperinflation compared to healthy individuals, but
diaphragm mobility was higher during resting breathing in
individuals with COPD due to the increase in inspiratory
effort caused by pulmonary hyperinflation [15]. Jain et al.
revealed that diaphragm mobility decreased in individuals
with mild COPD compared to the control group, and it
increased in individuals with moderate and severe COPD
[25]. The researchers stated that the decrease in diaphragm
mobility was due to air trapping and hyperinflation, and
they could not fully explain the reason for the increase
in diaphragm mobility. However, it was indicated that
increased airway obstruction might lead to hypoxia
and hyperventilation resulting in increased diaphragm
mobility. In our study, it was observed that diaphragm
mobility decreased in individuals with COPD. When
other studies in the literature are reviewed, we think
that this may be due to the shortening of the apposition
region because of the lack of piston-like movement of the
diaphragm as a result of air trapping in individuals with
COPD and the structural changes of the diaphragm.
The diaphragm thickening fraction is used as an
indirect measure of muscle fiber contraction, similar
to the ejection fraction of the heart. It has recently been
shown that the diaphragm thickening fraction is more
sensitive than diaphragm thickness measurement in
reflecting diaphragm contraction [30]. Elsawy found no
difference in diaphragm thickness between the COPD
and control groups but revealed that the diaphragm
thickening fraction was lower in individuals with COPD
[14]. According to this result, it was revealed that the
contractility of the diaphragm might change in individuals
with COPD. Abd El Aziz et al. also found that the amount
of diaphragm thickening decreased in individuals with
COPD [23]. Baria et al. on the other hand stated that the
thickening ratio and diaphragm thickness did not change
in individuals with COPD and that diaphragm dysfunction
might reflect the mechanical impairment of diaphragm
mobility secondary to pulmonary hyperinflation rather
than physiological changes in contractility [19]. In our
study, it was observed that the thickening fraction, the
amount of thickening, and the thickening ratio decreased
in individuals with COPD. According to our inferences
from other studies in the literature, we think that the
reason for this may be the force-length relationship that
limits the contractility as a result of the shortening of the
diaphragm, which is positioned in a nonoptimal position
due to hyperinflation. In this study, it was determined that
the right side diaphragmatic thickening fraction and ratio
changed according to the severity of the disease; on the left
side, it was seen that it did not change. We think that this
is because the left hemidiaphragm has a smaller range of
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motion due to the spleen and its movement is restricted by
the enlarged lung. Amin et al. also stated that the right side
mobility is higher than the left side in diaphragm mobility
due to the anatomical structure originating from the spleen
[31]. Moreover; the right diaphragm displacement may be
more pronounced because the dome is more prominent in
the right hemidiaphragm due to the weight of the heart.
Decreased left diaphragmatic mobility may affect the
thickening fraction and ratio.
Abd El Aziz et al. demonstrated that diaphragm
thicknesses at TLC, FRC, and RV decreased with the
increase in COPD severity and were associated with
FEV1, FVC, and FEV1/FVC [23]. El-hay et al. also stated
that TLC and FRC diaphragm thicknesses decreased with
disease severity [32]. It was indicated in this study that
the decrease in diaphragm thickness in individuals with
severe COPD might be due to a high FRC/TLC ratio in
addition to the weakened diaphragm. Ogan et al. found
no relationship between diaphragm thickness and FEV1
[26]. In their study, they emphasized that pulmonary
hyperinflation affected diaphragm mobility rather than
diaphragm thickness, and mobility better-reflected
diaphragm function. Smargiassi et al. showed that TLC
diaphragm thickness was associated with air trapping
parameters (directly with IC/TLC, inversely with FRC/
TLC and RV/TLC) [33]. In conclusion, they suggested
that TLC diaphragm thickness could be a useful tool to
predict pulmonary hyperinflation. Elsawy showed that
the thickening fraction decreased as the severity of the
disease increased [14]. However, FEV1% and FEV1/FVC
were associated with thickening fraction, whereas FVC%
and FEF25-75% were not. In this study, it was observed
that the most important factors affecting the thickening
fraction were FEV1%, FVC%, and FEF25–75%. These results
demonstrated that the diaphragm suffers from mechanical
disadvantages (nonoptimal length-tension relationship of
muscle fibers) with increasing COPD severity, and thus
contractility decreases. Smargiassi et al. showed that the
amount of thickening was associated with hyperinflation,
air trapping (directly with IC/TLC, inversely with FRC/
TLC and RV/TLC), and dynamic pulmonary volumes
(VC, FRC, and FEV1) [33]. Therefore, airflow restriction
resulting in air trapping and pulmonary hyperinflation
was demonstrated to play a major role in the dynamic
thickening process. Likewise, Hafez et al. based the
association of thickening fraction with FEV1 on the
fact that airway obstruction, which increases with the
progression of COPD, causes dynamic air trapping and
limits its contractility [34]. Corbellini et al. demonstrated
that diaphragm mobility was associated with IC and IC/
TLC in their study examining individuals with moderate,
severe, and very severe COPD and stated that this was
caused by the effect of dynamic pulmonary hyperinflation
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on diaphragm mobility [15]. Yamaguti et al. also showed
that diaphragm mobility was strongly associated with FEV1
and parameters reflecting air trapping (RV and RV/TLC)
and weakly associated with pulmonary hyperinflation
(TLC) [28]. In the study, it was concluded that there was a
close interaction between impaired respiratory mechanics
and the severity of abnormal pulmonary function in
COPD patients. In our study, in parallel to the literature,
PFT parameters other than FEV1/FVC were found to be
associated with diaphragm thickness, diaphragm mobility,
and amount of diaphragm thickening. We think that the
reason for this is mechanical changes that occur with air
trapping and pulmonary hyperinflation resulting from
the increase in disease severity. There is a need for new
studies explaining the reasons for the relationship between
diaphragm ultrasound parameters and PFT parameters.
Moreover, the thickening fraction and ratio on the right
side were associated with FEV1%, FVC%, and MEF 50%;
no association was found on the left side. We think that
this is due to the reduced range of motion in the left
hemidiaphragm due to anatomical reasons. Diaphragm
ultrasound parameters were not associated with BMI,
symptom, and comorbidity score; however, it was
associated with dyspnea. We think that this may be due to
the fact that the deterioration in respiratory mechanics due
to the decrease in diaphragm movement can increase the
perception of dyspnea. Cimsit et al. found no correlation
between diaphragm thickness and symptom scores (CAT
and MMRC) [35]. Eryuksel et al. found no correlation
between diaphragm thickening fraction and MMRC and
CAT scores [36]. Rocha et al. found a relationship between
diaphragm mobility and dyspnea perception. In the study,
it was shown that changes in the diaphragm position
make ventilation difficult, reduce respiratory capacity and
increase the perception of dyspnea [37]. New studies are
needed to explain the reasons for the relationship between
diaphragm ultrasound parameters, PFT parameters,
symptoms and comorbidity. Our study had limitation.
Due to the high prevalence of COPD in males and patient
flow, all of the individuals included in the study were
male. Comparisons could be made in terms of gender by
including female individuals in the assessment.
In conclusion, it was found that diaphragm thickness,
mobility, and diaphragm thickening fraction decreased
with the increase in disease severity in individuals with
COPD, and diaphragm ultrasound parameters were
associated with pulmonary function test parameters.
We think that adding diaphragm ultrasound parameters
together with pulmonary function test to the evaluation
of individuals with COPD will provide additional
contributions to determining the course of the disease.
Moreover, it would be useful to evaluate diaphragm
ultrasound parameters in individuals with COPD whose
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clinical condition is unpredictable. It was thought that
adding diaphragm ultrasound parameters in addition to a
routine pulmonary evaluation in individuals with COPD
would be clinically important. Moreover, there is a need
for new studies examining individual-specific pulmonary
rehabilitation programs to increase diaphragm thickness
and mobility.
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